

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (DE-150)

COFETUZUMAB PELIDOTIN

PRONUNCIATION

koe" fe tooz' ue mab pel" i doe' tin

THERAPEUTIC CLAIM

Oncology

CHEMICAL NAMES

1. Immunoglobulin G1, anti-(human protein tyrosine kinase 7) (humanized *Mus musculus* clone hu24 γ -chain), disulfide with humanized *Mus musculus* clone hu24 κ -chain, dimer, thioether with *N*-[[[4-[[*N*-[6-(2,5-dihydro-2,5-dioxo-1*H*-pyrrol-1-yl)-1-oxohexyl]-*L*-valyl-*N*⁵-(aminocarbonyl)-*L*-ornithyl]amino]phenyl]methoxy]carbonyl]-2-methylalanyl-*N*-[(1*S*,2*R*)-2-methoxy-4-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-2-methyl-3-oxo-3-[(1*S*)-2-phenyl-1-(2-thiazolyl)ethyl]amino]propyl]-1-pyrrolidinyl]-1-[(1*S*)-1-methylpropyl]-4-oxobutyl]-*N*-methyl-*L*-valinamide
2. Immunoglobulin G1-kappa, anti-(human inactive tyrosine-protein kinase 7 (colon carcinoma kinase 4, CCK-4, protein-tyrosine kinase 7)), humanized mouse monoclonal antibody conjugated to dolastatin 10 derivative; γ 1 heavy chain (1-448) [humanized VH (*Homo sapiens* IGHV1-3*01 (82%) –(IGHD)-IGHJ4*01 (86%)) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 {CH3 K¹⁰⁷>-(449)} (120-448)], (222-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens* IGKV3-11*01 (84%) –IGKJ4*01) (91%) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218')], dimer (228-228":231-231")-bisdisulfide; an average of 4 cysteine residues are S substituted with (3*RS*)-1-(6-[[{(2*S*)-1-[[{(2*S*)-5-(carbamoylamino)-1-[4-[[{(1-[[{(2*S*)-1-[[{(3*R*,4*S*,5*S*)-3-methoxy-1-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-2-methyl-3-oxo-3-[(1*S*)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl)-5-methyl-1-oxoheptan-4-yl](methyl)amino}-3-methyl-1-oxobutan-2-yl]amino}-2-methyl-1-oxopropan-2-yl)carbamoyl]oxy}methyl]anilino]-1-oxopentan-2-yl}amino)-3-methyl-1-oxobutan-2-yl]amino}-6-oxohexyl)-2,5-dioxopyrrolidin-3-yl radical

STRUCTURAL FORMULA

Heavy chain

QVQLVQSGPE	VKKPGASVKV	SCKASGYTFT	DYAVHWVRQA	PGKRLEWIGV	50
I ^u STYNDYTYN	NQDFKGRVTM	TRDTSASTAY	MELSLR ^u LRSED	TAVYYCARGN	100
SYFYALDYWG	QGTSTVTSSA	STKGPSVFPL	APSSKSTSGG	TAALGCLVKD	150
YFPEPVTVSW	NSGALTSGVH	TFFPAVLQSSG	LYSLSSVTV	PSSSLGTQTY	200
ICNVNHKPSN	TKVDK ^u KVEPK	SCDKTHTCPP	CPAPELLGGP	SVFLFPPKPK	250
DTLMISR ^u TPE	VTCVVDVSH	EDPEVKFNWY	VDGVEVHNAK	TKPREEQYNS	300
TYRVVSVLTV	LHQDWLNGKE	YKCKVSNKAL	PAPIEKTISK	AKGQPREPQV	350
YTLPPSRDEL	TKNQVSLTCL	VKGFYPSDIA	VEWESNGQPE	NNYKTTPPV ^u L	400
DSDGSFFLYS	KLTVDKSRWQ	QGNVFSCSVM	HEALHNHYTQ	KSLSLSPG	448


Light chain

EIVLTQSPAT	LSLSPGERAT	LSCRASESVD	SYGKSFMHWY	QKPGQAPRL	50'
LIYRASNLES	GIPARFSGSG	SGTDFTLTIS	SLEPEDFAVY	YCQQSNEDPW	100'
TFGGGTKLEI	KRTVAAPSVF	IFPPSDEQLK	SGTASVVCLL	NNFYPREAKV	150'
QWKVDNALQS	GNSQESVTEQ	DSKDSTYSLS	STLTLSKADY	EKKHKVYACEV	200'
THQGLSSPVT	KSFNRGEC				218'

Disulfide bridges

22-96	22"-96"	23'-92'	23'''-92'''	138'-198'	138'''-198'''	146-202	146"-202"
218'-222	218'''-222'''	228-228"	231-231"	263-323	263'''-323'''	369-427	369"-427"

Modified residues



Glycosylation sites (N)

Asn-299 Asn-299"

MOLECULAR FORMULA $C_{6774}H_{10418}N_{1778}O_{2096}S_{46}$ (nonglycosylated)

MOLECULAR WEIGHT 151.7 kDa (nonglycosylated, $n = 4$)

TRADEMARK None as yet

SPONSOR Pfizer Inc.

CODE DESIGNATIONS PF-06647020

CAS REGISTRY NUMBER 1869937-48-3

UNII 249EAP69MT

WHO NUMBER 10674

gbk